Topics

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

2019-08-13 18:05:44 | BioPortfolio

Summary

A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of sIBM

Study Design

Conditions

Inclusion Body Myositis

Intervention

Arimoclomol

Location

Phoenix Neurological Associates
Phoenix
Arizona
United States
85018

Status

Enrolling by invitation

Source

Orphazyme

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-08-13T18:05:44-0400

Clinical Trials [119 Associated Clinical Trials listed on BioPortfolio]

Arimoclomol in Sporadic Inclusion Body Myositis

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability o...

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood an...

Natalizumab in Inclusion Body Myositis (IBM)

Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death m...

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of arimoclomol in subjects with SOD1 positive familial ALS. This type of ALS is HEREDITARY (runs in ...

Study of Pioglitazone in Sporadic Inclusion Body Myositis

A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

PubMed Articles [4898 Associated PubMed Articles listed on BioPortfolio]

CD8 +  cells as a predominant biomarker for inclusion body myositis.

Myositis is a heterogeneous group of muscular auto-immune diseases with clinical and pathological criteria that allow the classification of patients into different sub-groups. Inclusion body myositis ...

Highly differentiated cytotoxic T cells in inclusion body myositis.

Inclusion body myositis is a late onset treatment-refractory autoimmune disease of skeletal muscle associated with a blood autoantibody (anti-cN1A), an HLA autoimmune haplotype, and muscle pathology c...

Assessing the Accuracy of Neuromuscular Ultrasound for Inclusion Body Myositis.

Inclusion body myositis (IBM) can have clinical and electrodiagnostic features similar to other neuromuscular diseases, making it a diagnostic challenge. This prospective study was designed to determi...

Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity.

Although more than a dozen myositis-specific autoantibodies (MSAs) have been identified, most myositis patients produce a single MSA. The specific overexpression of a given myositis autoantigen in myo...

Resistance Exercise Improves Mitochondrial Quality Control in a Rat Model of Sporadic Inclusion Body Myositis.

Mitochondrial dysfunction is implicated in the pathogenesis of multiple muscular diseases, including sporadic inclusion body myositis (s-IBM), the most common aging-related muscle disease. However, th...

Medical and Biotech [MESH] Definitions

Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)

A disease characterized by bony deposits or the ossification of muscle tissue.

A genus of DNA viruses in the family PAPILLOMAVIRIDAE, which cause cutaneous lesions in humans. They are histologically distinguishable by intracytoplasmic INCLUSION BODIES which are species specific.

Circumscribed masses of foreign or metabolically inactive materials, within the CELL NUCLEUS. Some are VIRAL INCLUSION BODIES.

Inflammation of a muscle or muscle tissue.

More From BioPortfolio on "Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial"

Quick Search

Relevant Topic

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...


Searches Linking to this Trial